Interrupted Glucagon Signaling Reveals Hepatic α Cell Axis and Role for L-Glutamine in α Cell Proliferation.

[1]  A. Murphy,et al.  Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice. , 2017, Cell metabolism.

[2]  R. Unger,et al.  Glucagon antagonism in islet cell proliferation , 2017, Proceedings of the National Academy of Sciences.

[3]  R. Tian,et al.  Defective Branched-Chain Amino Acid Catabolism Disrupts Glucose Metabolism and Sensitizes the Heart to Ischemia-Reperfusion Injury. , 2017, Cell metabolism.

[4]  Kyoung-Jae Won,et al.  Single cell transcriptomic profiling of mouse pancreatic progenitors. , 2017, Physiological genomics.

[5]  A. Murphy,et al.  Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition , 2017, Proceedings of the National Academy of Sciences.

[6]  J. Holst,et al.  Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis , 2017, Diabetes.

[7]  J. Holst,et al.  Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation , 2016, Endocrinology, diabetes & metabolism case reports.

[8]  P. Wang,et al.  Development of a reliable automated screening system to identify small molecules and biologics that promote human β-cell regeneration. , 2016, American journal of physiology. Endocrinology and metabolism.

[9]  A. Murphy,et al.  RNA Sequencing of Single Human Islet Cells Reveals Type 2 Diabetes Genes. , 2016, Cell metabolism.

[10]  Mee-Sup Yoon.  The Emerging Role of Branched-Chain Amino Acids in Insulin Resistance and Metabolism , 2016, Nutrients.

[11]  R. Stein,et al.  Stress-impaired transcription factor expression and insulin secretion in transplanted human islets. , 2016, The Journal of clinical investigation.

[12]  Frank B Hu,et al.  Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis , 2016, Diabetes Care.

[13]  I. Modlin,et al.  Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome , 2016 .

[14]  B. Viollet,et al.  Proglucagon Promoter Cre-Mediated AMPK Deletion in Mice Increases Circulating GLP-1 Levels and Oral Glucose Tolerance , 2016, PloS one.

[15]  Y. Bao,et al.  Branched-chain and aromatic amino acid profiles and diabetes risk in Chinese populations , 2016, Scientific Reports.

[16]  D. Melton,et al.  Angptl4 links α-cell proliferation following glucagon receptor inhibition with adipose tissue triglyceride metabolism , 2015, Proceedings of the National Academy of Sciences.

[17]  Yun Zheng,et al.  Elusive liver factor that causes pancreatic α cell hyperplasia: A review of literature. , 2015, World journal of gastrointestinal pathophysiology.

[18]  A. Powers,et al.  Glucagon receptor inactivation leads to α-cell hyperplasia in zebrafish. , 2015, The Journal of endocrinology.

[19]  O. Fiehn,et al.  Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass. , 2015, Cell reports.

[20]  Y. Takagishi,et al.  Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides , 2015, PloS one.

[21]  D. Drucker,et al.  Islet α cells and glucagon—critical regulators of energy homeostasis , 2015, Nature Reviews Endocrinology.

[22]  C. A. French,et al.  The FOXP1, FOXP2 and FOXP4 transcription factors are required for islet alpha cell proliferation and function in mice , 2015, Diabetologia.

[23]  A. Murphy,et al.  Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys. , 2015, Endocrinology.

[24]  W. Bush,et al.  Human islet preparations distributed for research exhibit a variety of insulin-secretory profiles. , 2015, American journal of physiology. Endocrinology and metabolism.

[25]  M. Scalise,et al.  Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health , 2014, Front. Chem..

[26]  C. Donaldson,et al.  The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression , 2014, BMC Genomics.

[27]  C. Farber,et al.  Glucagon regulates hepatic kisspeptin to impair insulin secretion. , 2014, Cell metabolism.

[28]  S. Levy,et al.  Islet microenvironment, modulated by vascular endothelial growth factor-A signaling, promotes β cell regeneration. , 2014, Cell metabolism.

[29]  Rohit N. Kulkarni,et al.  Human β-Cell Proliferation and Intracellular Signaling , 2012, Diabetes.

[30]  Ralph J DeBerardinis,et al.  Glutamine and cancer: cell biology, physiology, and clinical opportunities. , 2013, The Journal of clinical investigation.

[31]  D. Drucker,et al.  Liver-Specific Disruption of the Murine Glucagon Receptor Produces α-Cell Hyperplasia , 2013, Diabetes.

[32]  J. Schug,et al.  Epigenomic plasticity enables human pancreatic α to β cell reprogramming. , 2013, The Journal of clinical investigation.

[33]  P. Massion,et al.  SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival , 2012, Clinical Cancer Research.

[34]  C. Newgard.  Interplay between lipids and branched-chain amino acids in development of insulin resistance. , 2012, Cell metabolism.

[35]  Daniel C. Liebler,et al.  Global Stability of Plasma Proteomes for Mass Spectrometry-Based Analyses* , 2012, Molecular & Cellular Proteomics.

[36]  A. Cherrington,et al.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. , 2012, The Journal of clinical investigation.

[37]  R. Stein,et al.  Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets , 2011, Diabetologia.

[38]  J. Schug,et al.  Transcriptomes of the major human pancreatic cell types , 2011, Diabetologia.

[39]  S. Ren,et al.  Pancreatic Neuroendocrine Tumors in Glucagon Receptor-Deficient Mice , 2011, PloS one.

[40]  J. Treadway,et al.  Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes , 2011, BMC Genomics.

[41]  D. Sabatini,et al.  Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. , 2011, Cancer cell.

[42]  Katherine A. Winters,et al.  Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible α-Cell Hyperplasia and Hyperglucagonemia , 2009, Journal of Pharmacology and Experimental Therapeutics.

[43]  Run Yu,et al.  Homozygous P86S Mutation of the Human Glucagon Receptor Is Associated With Hyperglucagonemia, &agr; Cell Hyperplasia, and Islet Cell Tumor , 2009, Pancreas.

[44]  V. Gundersen,et al.  Complementary expression of SN1 and SAT2 in the islets of Langerhans suggests concerted action of glutamine transport in the regulation of insulin secretion. , 2009, Biochemical and biophysical research communications.

[45]  D. Drucker,et al.  The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting , 2022 .

[46]  R. Woodland,et al.  A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. , 2008, Clinical immunology.

[47]  Elias Chaibub Neto,et al.  Genetic Networks of Liver Metabolism Revealed by Integration of Metabolic and Transcriptional Profiling , 2008, PLoS genetics.

[48]  B. Reusens,et al.  Fetal determinants of type 2 diabetes. , 2007, Current drug targets.

[49]  David Millington,et al.  Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance , 2004, Nature Medicine.

[50]  J. Holst,et al.  Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Stock,et al.  Glycemic control in mice with targeted disruption of the glucagon receptor gene. , 2002, Biochemical and biophysical research communications.

[52]  G. Pardi,et al.  Maternal concentrations and fetal-maternal concentration differences of plasma amino acids in normal and intrauterine growth-restricted pregnancies. , 1996, American journal of obstetrics and gynecology.

[53]  K. Nicolaides,et al.  Plasma amino acids in appropriate‐ and small‐for‐gestational‐age fetuses , 1990, American journal of obstetrics and gynecology.

[54]  R. Unger,et al.  Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. , 1968, The Journal of clinical investigation.

[55]  B. Petersson,et al.  EFFECTS OF LONG TERM ADMINISTRATION OF GLUCAGON ON THE PANCREATIC ISLET TISSUE OF RATS AND GUINEA-PIGS. , 1963, Acta endocrinologica.

[56]  Wenbiao Chen,et al.  Generation of Targeted Mutations in Zebrafish Using the CRISPR/Cas System. , 2015, Methods in molecular biology.

[57]  渡邊 智香.  Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides , 2012 .

[58]  M. Damore,et al.  Dysregulation of Glucagon Secretion in Glucagon Receptor Null Pancreatic Islets , 2008 .

[59]  M. Ziegler,et al.  [A-cell-hyperplasia of islets of Langerhans on rabbits after immunisation with glucagon (author's transl)]. , 1981, Acta histochemica.

[60]  H. H. V. Dorsche,et al.  A-Zellenhyperplasie der Langerhansschen Inseln von Kaninchen nach Immunisierung mit Glukagon , 1981 .